2022

1. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

   European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 222-227